A colapsible company promotes colapsible sringe hence ........prices.

Chance.

Monday, September 29, 2003 7:50:25 AM ET
Dryden Financial

LONDON, September 29 (New Ratings) - Analysts at Dryden Financial issue a "buy" rating on the Smiths Group (SMIN).

In a research note published this morning, the analysts mention that although the company had planned to promote the Medisys safety syringe in the US market, the actual customer performance results belied the test trials. Despite the acrimonious parting of ways, neither Smiths nor Medisys stands to lose, the analysts say. Dryden Financial believes that both companies have bright prospects.

2003 New Ratings

http://www.advfn.com/cmn/fbb/thread.php3?id=3982666

Like this !!

http://www.wallstreetreporter.com/profiles/Medisys.html

yes i would to khow why this company has been let down by smiths the big company that was going to help medisys launch the new product safety syringe???????????i hope you can let me know any other info.thanks moneyman

Old article but very apt at the moment

http://www.mis-limited.co.uk/BBIC/review/med%2015-11-01.htm

moneyman the article is so out-of-date it is of historical interst I grant you. The brief survey refers to a stop-loss of 70p
Only wish I had! oit reached 1.20 - I did sell out at 50p-ish and then bought back as the slide occured - with a final buy at 4.5pence as I recall.
Hence by seling-out I avoided the final throes of the various delays - it has been these delays that have upset Smiths. (syringes only - the rest of their range is fine and fit as far as I know - but then I KNOW very little and a lot less than the market. My average-price is about today's level.

I'm waiting for some real news - like a deal in US - but who would take Futura ( a damn silly name IMHO), now? I am still a small-holder, if that helps.

Hangon there is so much bad press out there that i fully i=understand what you mean however the potential market is huge and the first glimmer of hope will propel MDY far higher than it's measly price of 12p.

The potential size of the market doesn't matter, if you'lll excuse me saying -

If I claim to have invented a process to turn tap-water into fuel to drive a car ( chemically quite easy!) there is "massive potential" and maybe in a Bull Market, with some help I could pull off a big scam ( er, I mean create shareholder value, protected by patents ).
However, you should be asking me not about the "potential" but the regulation, safety, competition, cost to achieve even 1% of the "potential".....but rarely do "we investos" think like that.
The Question IMHO for Medisys is will their existing product sustain their costs until they can manufacture (or license) the retractable syringe, which still has a logical flaw: the needle is exposed just prior to the injection.

Also, my local chemists are selling a competing diabetic reader for 10 - MDY test-strips may be profitable: provided people buy their reader, I presume. They have other products I know, but the needle is the one that has the "potential" isn't it?

The company has been silent on the Smiths debacle and we may yet have to endure a legal wrangle over the payments - - -all at shareholder expense.

The real question is simple: Will shareholders make any Return?
Look at trend in shareprice over the last 3 years I think the answer is "unlikely" - it would be wonderful if it came good, but sometimes history is a good predictor of the unknown future.
I hold MDY from lower prices.
AGM is later in March04.

From today's buys it looks like there is credibility to the claims on yesterday's other financial message boards.Is this the start of the ascent?
Can anybody throw any light on today's surge?

Well we don't usually see volume like this unless something has leaked.The size of some of the trades indicated that someone is building a position here.
Time to add further I think !

Let's summarise MDY at the moment;

We have seen the company become EBITDA positive for the first time in it's history.The growth of the company,without taking further product launches into consideration,has been phenominal.Having traded at 20p+ for a considerable time the stock was hit hard by the market conditions and also the parting of company with it's proposed distributor for the Futura safety syringe Smiths Industries.

Facts today are that we have a broker buy note out,although the house broker,valueing the stock at over 20p without factoring in the launch of Flight to Walmart or Futura through Medisys's internal sales force.

Today we had a very large peak in volume which typically,for those that follow MDY,signifies a news leak.This also coincided with some large trades going through the system in blocks of 500K.

Interviews with the CEO have said that the Futura syringe will launch in early Q2.The delay has been in the changing of the packaging which is probaly due to the Smiths departure.We also expect that the Flight blood glucose monitor will be on Walmarts shelves imminently.

We have an AGM weeks away where confirmation of these two launches will probably be confirmed. This will lead to a massive re-rating of the stock and hopefully city confidence in Medisys will be rstored thus gaining institutional coverage.

The market for safety syringes is a growing one and if Medisys have the right product,at the right price,selling through the right channels then this could be a potential goldmine of a stock.

It is now up to the management to prove to us the shareholder that they will deliver according to their promises.

Happy to hold and wait for that dream to become a reality......soon !

Medisys PLC
03 March 2004



Embargoed until 0700 3 March 2004


Medisys PLC

('Medisys' or 'the Group')


Hypoguard Named in Complaint for Patent Infringement

Medisys announces that Hypoguard, the Group's diagnostics division, has been
named as one of four defendants in a Complaint For Patent Infringement made by
Roche Diagnostics Corporation in the Indianapolis Division of the United States
District Court. The other named defendants are Apex Biotechnology Corp.
('Apex'), Medline Industries, Inc. and Home Diagnostics, Inc.

The Complaint alleges that the use and sale of the Assure family of blood
glucose monitoring system products, which includes Assure, Assure II and Assure
3, infringe two patents owned by Roche. The Assure products are manufactured
and supplied to Hypoguard by Apex under the terms of a supply and distribution
agreement (the 'Agreement'). The Agreement includes an indemnity, given by Apex
to Hypoguard, for liability arising from the Assure products infringing the
intellectual property of a third party. Apex has confirmed that it will stand
behind such indemnity in relation to Roche's Complaint.

Hypoguard is currently investigating the validity of the patents cited by Roche
in the Complaint and assessing whether or not the allegations in Roche's
Complaint have any merit. Following the completion of this exercise Hypoguard
will respond to the Complaint and further update shareholders.


- Ends -


Enquiries:
Medisys PLC 020 7563 5200
Michael Barry, Chief Financial Officer

Weber Shandwick Square Mile 020 7067 0700
Terry Garrett /Susanne Walker